Aortic stiffness is an important predictor of future morbidity and mortality. Diabetes is associated with increased aortic stiffness, but the importance of nondiabetic glucometabolic status for accelerated aortic stiffening is unclear. We tested the hypothesis that adverse glucometabolic status is associated with accelerated aortic stiffening in individuals without diabetes, independently of known risk factors for arterial stiffening.
the aging process (5) . A number of risk factors for accelerated aortic stiffening have been described, including elevated blood pressure, renal disease, systemic inflammation, and adiposity (6) (7) (8) (9) (10) . Diabetes has been linked with increased vascular stiffness in several case-control studies (11) (12) (13) , and HbA 1c level is associated with an accelerated age-related increase in cfPWV in individuals with type 2 diabetes (14) . Cross-sectional studies in individuals without diabetes suggest an association between aortic stiffness, glycemia, and indices of insulin resistance (11, 15, 16) . However, a prospective analysis using Whitehall II data are equivocal, finding associations only in men (17) . The evidence from longitudinal studies is also conflicting. Only one of seven previous longitudinal studies identified plasma glucose as an independent predictor of the rate of progression of cfPWV after adjusting for confounders, but only in women (18) . The remaining longitudinal studies either report no independent association (19) (20) (21) (22) or did not examine glucose as a risk factor for stiffening (23, 24) . None of the studies provide any information concerning HbA 1c and aortic stiffening.
We hypothesized that impaired glycemic control is associated with accelerated aortic stiffening in individuals without diabetes and that this would be independent of known risk factors for arterial stiffening. Our aim was to test this hypothesis in the Whitehall II longitudinal study. This cohort study provides data on progression of cfPWV during a 4-year interval, together with repeated assessments of glycemia, insulin resistance, anthropometric parameters, and cardiovascular risk factors. We excluded individuals with clinical or biochemical evidence of diabetes to reduce the confounding effects of treatment and diabetic complications, such as renal disease, which may themselves alter stiffness.
RESEARCH DESIGN AND METHODS

Participants
All participants were drawn from the Whitehall II cohort, a longitudinal observational study of 10,308 civil servants recruited between 1985 and 1988 when aged 35-55 years (25) Committee approval was obtained for each examination phase, and participants gave written informed consent.
The cfPWV was assessed in 4,347 of 6,225 participants seen at the screening clinic in 2008-09 and in 4,485 of 5,660 seen in 2012-13. The present analysis was based on participants without diabetes. Diabetes was defined by self-report/ doctor diagnosis, the use of antidiabetic medication, fasting glucose $7.0, a 2-h glucose $11.1 mmol/L during an oral glucose tolerance test, or HbA 1c $6.5% (48 mmol/mol). Excluded from the analysis were 617 participants who met these criteria at baseline and 582 at follow-up, together with a further 95 participants at baseline and 301 at follow-up who had missing data on covariates. This left 4,386 participants without diabetes who underwent cfPWV assessment during the 2008-09 (n = 3,685) and/or 2012-13 (n = 3,602) examinations who make up the analytic sample. The cfPWF was assessed in 2,901 participants at both time points. The same measurement protocol was used at each examination.
Measurements
PVW
Aortic stiffness was assessed by cfPWV, the current noninvasive gold standard (26) . Higher values of cfPWV indicate a faster speed of wave travel between the arterial sites and, hence, a stiffer aorta. Measurements were made after a 15-min supine rest, in duplicate, using the SphygmoCor system (AtCor Medical, Sydney, NSW, Australia), as previously described (27) . Briefly, brachial blood pressure was measured and then cfPWV assessed between the carotid and femoral sites. Path length was determined with a tape measure by subtracting the carotid-sternal notch distance from the femoral-sternal notch distance. If the difference between repeated measurements was .0.5 m/s, a third measurement was taken, and the average of the measurements was used in the analysis. Heart rate was derived from the SphygmoCor software, and blood pressure was measured using a validated oscillometric device immediately before cfPWV. Mean arterial pressure (MAP) was calculated as diastolic pressure plus one-third of the pulse pressure. (29) . Serum, fluoride plasma, and blood drawn into EDTA tubes was collected after an overnight fast or $5 h after a fat-free breakfast for participants presenting in the afternoon. Serum total cholesterol, HDL cholesterol, triglycerides, and plasma glucose were measured.
Glucometabolic Measures
Samples were handled according to standard protocols. Venous blood samples were taken in fasted individuals ($8 h fasting or $5 h for afternoon visits), before a standard 2-h oral glucose tolerance test was administered in all participants (29) . Glucose samples were drawn into fluoride Monovette tubes and insulin samples into native tubes that were centrifuged on site within 1 h. Plasma or serum was immediately moved into microtubes and stored at -70°C. Blood glucose was measured using the glucose oxidase method (30) 
Statistical Analysis
Distributions of glucometabolic indices among people without diabetes were categorized in sex-specific quintiles and also expressed in standardized units. Linear mixed models were used to estimate the relation of glucometabolic indices with cfPWV in 2008-09 and change in cfPWV between 2008-09 and 2012-13. These models used all available cfPWV data, including cases where only one cfPWV measurement was available, which reduced selection bias and allowed better estimates of the associations of potential confounding factors. The models also accounted for correlation between repeated measures within individuals. We fitted the models with a random intercept and slope to account for individual differences in cfPWV at baseline and rate of change during follow-up. From these models, the effect of each glucometabolic index on cfPWV at baseline (2008-09) is estimated by the coefficient for the main effect of the glucometabolic index, and the effect on progression of cfPWV between 2008-09 and 2012-13 is estimated by the interaction of the main effect with time. The longitudinal effects of the glucometabolic indices are expressed as 5-year changes in cfPWV to allow direct comparisons with previous studies (18, 20, 24) . All estimates were initially adjusted for age, sex, ethnic group, heart rate, and MAP at the time of cfPWV measurement. Baseline cfPWV and progression of cfPWV per 5 years were estimated from these models by quintile of each glucometabolic index distribution and per 1 SD increment in each index. This allowed us to examine associations with cfPWV across the distribution of each glucometabolic index and whether the coefficients increased linearly across quintiles. Tests of heterogeneity were conducted using likelihood ratio tests that compared the fit of the models with and without the quintiles of each glucometabolic measure. 
RESULTS
The cohort at the time of the baseline cfPWV assessment was a mean age of 60 years, 74% male, and predominantly of white ethnic origin. Fewer than 5% had chronic disease, and ;30% were taking antihypertensive medication. A comparison of participants with and without cfPWV assessments across the entire cohort revealed that those individuals who did not have cfPWV measured were more likely to be female and have generally poorer health, in terms of chronic disease and taking antihypertensive or lipidlowering medication (Supplementary Table 1 ). Detailed participant characteristics at the time of the two cfPWV examinations are provided in Table 1 . Measures of exposure that were averaged across the prebaseline (2003-04) and baseline (2008-09) cfPWV visits are presented separately for each examination phase in Supplementary Table 2 .
There was no evidence that the associations of the glucometabolic indices with baseline cfPWV and progression of cfPWV differed between men and women (Supplementary Table 3 ). Cross-sectional associations between cfPWV and glucometabolic indices are shown by quintile in Table 2 , adjusted for age, sex, ethnicity, MAP, and heart rate. Significant positive associations were found with fasting glucose, 2-h glucose, HbA 1c , and HOMAinsulin resistance (HOMA-IR). cfPWV increased by between 0.19 and 0.40 m/s when moving from the lowest to highest quintile of each determinant. Additional adjustment for other potential confounders, including drug therapy and cardiovascular risk factors, only modestly attenuated these associations (Supplementary Table 4 ). When glucometabolic measures were treated as continuous variables, glucose and HOMA-IR were strongly associated and HbA 1c was weakly associated with baseline cfPWV (Table 3) . These associations were weakened with additional adjustment for potential confounders.
After adjustment for age, sex, ethnicity, MAP, and heart rate, only HbA 1c and HOMA-IR were significantly associated with progression of cfPWV. There was a 0.39 m/s greater increase in cfPWV over 5 years in individuals in the top quintile of either parameter compared with those in the lowest quintile (Table 2 and Fig. 1 ). Adjustment for treatment and other risk factors (Supplementary Table 5 ) did not significantly attenuate these associations. However, after the addition of BMI to the models, there was no longer an association with HOMA-IR. Analyses using the continuous variables revealed similar findings: a 1 SD higher HbA 1c or HOMA-IR at baseline was associated with a ;0.12 m/s greater increase in cfPWV over 5 years (Table 3 ). In the fully adjusted model, only HbA 1c was associated with progression in cfPWV.
Repeating these analyses using glucometabolic measures from baseline (2008-09) or prebaseline (2003-04), rather than averaging across the two phases, did not meaningfully alter the results (Supplementary Tables 6 and 7,  respectively) . Similarly, excluding the 1.1% of individuals who developed diabetes during follow-up had no influence on the results (data not shown). To exclude the possibility of a selection bias influencing our results because cfPWV was not measured in all participants, a separate analysis using the entire cohort explored the relationship between HbA 1c and blood pressure, which is closely related to cfPWV. At baseline and follow-up, HbA 1c was ;3% higher in hypertensive individuals than nonhypertensive individuals, in those with and without cfPWV assessment, after adjusting for confounding factors (Supplementary Table 8 ). This supports our observed association between HbA 1c and cfPWV and argues against the possibility that selection bias might be influencing our findings.
CONCLUSIONS
Our main findings are that glucose, HbA 1c , and insulin resistance are all crosssectionally associated with aortic stiffness and that longitudinal analysis shows HbA 1c and HOMA-IR are associated with the progression of aortic stiffness during a 4-year period. These associations were independent of other cardiovascular risk factors. The association between HbA 1c and aortic stiffening was also independent of BMI.
These observations suggest that factors underlying glucometabolic status may affect aortic stiffening even within the normoglycemic range, which may have important implications for developing antistiffening strategies and exploiting novel therapeutic targets.
Aortic stiffness, and cfPWV in particular, is an important risk factor for future cardiovascular disease independently of other cardiovascular risk factors (2) . However, the biological processes underlying aortic stiffening are incompletely understood. Cross-sectional analyses have provided inconsistent results (6) and are limited in their ability to attribute causality. Existing longitudinal data highlight the importance of age and blood pressure, but the importance of other potential risk factors, including indices of glucose homeostasis, is unclear because of lack of replication studies, variable lengths of follow-up, poor availability of data on individual risk factors, and variation in adjustment for confounders. Whitehall II is a large cohort with prospective data on cfPWV and other risk factors, including a variety of glucometabolic indices, making it well suited to examine the relationship between glycemia and aortic stiffening in individuals without diabetes.
As expected, we found significant cross-sectional relationships between indices of glucose homeostasis and insulin resistance with cfPWV. Importantly, this remained after adjustment for physiological confounders of stiffness such as MAP and heart rate (34). Similar results have been reported previously using a variety of study designs, indices of stiffness, and varying levels of adjustment for physiological confounders (11,15,16,35,36 ). In the current study, adjustment for other potential risk factors for arterial stiffening or cardiovascular disease only modestly reduced the strength of association with glucose measures, but the associations with HOMA-IR and HbA 1c were more markedly attenuated, with an approximate halving of the b-values. This contrasts with cross-sectional findings from a cohort of 263 African Americans (16), in whom HbA 1c but not fasting or 2-h glucose levels remained independently associated with cfPWV. This disparity possibly reflects ethnic differences in the association between HbA 1c and arterial stiffness or may reflect a lack of appropriate statistical power in the African American study. In addition, we a priori excluded individuals with diabetes, which may have removed any association with HbA 1c in our data. Alternatively, residual confounding may explain our observed associations with plasma glucose.
In contrast to the cross-sectional observations, fasting and 2-h glucose were not associated with progression of aortic stiffening in the current study, which is consistent with previous observations (19) (20) (21) (22) . However, HbA 1c and HOMA-IR were associated with accelerated progression of cfPWV independently of potential confounders. Previously, one small study reported no association between cfPWV progression and HOMA (19) , but HbA 1c has been associated with progressive carotid artery stiffening in the Atherosclerosis Risk in Communities (ARIC) Study (37) , although, unfortunately, cfPWV was not assessed. In the current study, cfPWV increased by ;0.7 m/s, which is consistent with previous longitudinal studies, which have reported increases of between 0.2 and 0.6 m/s per 5 years in participants aged ;60 years (18, 20, 24) . Moreover, modest differences of 0.07% in HbA 1c or 0.67 units in HOMA-IR were associated with an ;0.1 m/s greater increase in cfPWV over 5 years, equating to ;12-14% of the overall change in stiffness. Although the rate of stiffening is strongly dependent on age, our data suggest that even in individuals without diabetes, modest differences in glucometabolic status have a meaningful effect on arterial stiffening, consistent with our hypothesis of accelerated vascular aging.
A strong mechanistic relationship exists between measures of adiposity, insulin resistance, and glycemia. We and others have previously reported that measures of adiposity, including BMI, are associated with accelerated aortic stiffening independent of other risk factors (10, 18, 20, 22) ; therefore, we additionally adjusted for BMI. After this, HbA 1c but not HOMA-IR remained predictive of aortic stiffening. These findings suggest that adiposity and insulin resistance share common pathways leading to aortic stiffening but that these pathways may be independent of glycemia, although this hypothesis requires further examination. A number of mechanisms may be responsible, including visceral and perivascular fat accumulation and the vascular effects of insulin. Indeed, fasting insulin concentrations are positively associated with cfPWV in the general population (38) . In addition, abdominal and vascular adiposity alter adipokine levels, increase circulating proinflammatory stimuli, and may directly inflame the vasculature (39) (40) (41) . Low adiponectin levels have previously been associated with obesity and increased cfPWV progression (19) , and in the Whitehall II cohort, we have previously shown that a panel of inflammatory markers was associated with increased cfPWV 16 years later (17) . Systemic inflammation is also associated with cfPWV (7, 42) . Interestingly, the peroxisome proliferator-activated receptor g agonist, pioglitazone, improves inflammation and glycemic control in obese patients with diabetes (43) . Pioglitazone was also effective in preventing strokes (44) and in reducing the progression to diabetes and major cardiovascular events (45) in a high-risk population without diabetes. Peroxisome proliferatoractivated receptor g agonists may thus represent one potential therapeutic strategy to retard aortic stiffening in individuals without diabetes. In addition, formation of advanced glycation end products, which accumulate in tissues over time and with increased plasma glucose levels (46), correlate with aortic stiffness in individuals without diabetes (47, 48) . Experimental cross-link breakers reduce cfPWV and pulse pressure in animals (49) and humans (50), and our longitudinal finding for HbA 1c suggests that advanced glycation end products may represent another novel antistiffening target, even in individuals without diabetes. However, both of these hypotheses need to be tested in welldesigned intervention studies.
The current study has a number of limitations. We were restricted to 4-year follow-up data and cannot exclude the possibility that differences in relative strength of the glucometabolic risk factor effects may be observed with longer follow-up, or indeed, in younger adults. However, our data are consistent with observations made in other cohorts with similar lengths of follow-up. Moreover, we used the gold standard method of cfPWV to assess aortic stiffness and an identical protocol at both examinations. However, use of a 5-h fast for afternoon examinations may have meant that those participants were not truly fasted. We are unable to comment on the effect of diabetes per se because we a priori excluded individuals with diabetes. This allowed us to minimize potential confounding influences, such as therapy. However, we were able to demonstrate meaningful differences in progression of aortic stiffness, even within what is considered a normal range of HbA 1c . Given that glucometabolic indices determine the development of diabetes up to 15 years in advance (51) and cfPWV predicts future cardiovascular risk (2), we believe that our observations are clinically important and suggest that further mechanistic and intervention studies of arterial stiffening should examine factors related to longer-term glucometabolic status. These could involve lifestyle approaches and/or trials of glucoselowering therapies in individuals without diabetes, which could ultimately influence public health strategies.
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